Ken Griffin Black Diamond Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 400 shares of BDTX stock, worth $2,232. This represents 0.0% of its overall portfolio holdings.
Number of Shares
400
Previous 7,700
94.81%
Holding current value
$2,232
Previous $39,000
97.44%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding BDTX
# of Institutions
99Shares Held
47.3MCall Options Held
108KPut Options Held
24.8K-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.7MShares$59.5 Million0.03% of portfolio
-
Bellevue Group Ag Kuesnacht, V88.52MShares$47.5 Million0.66% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$24.8 Million1.96% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$18 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.13MShares$11.9 Million0.0% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $203M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...